

Resource Summary Report

Generated by PRECISE-TBI on Aug 14, 2026

Glutamate Dehydrogenase 1/2 (D9F7P)

RRID:AB_2750880

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 12793, RRID:AB_2750880

Antibody Information

URL: http://antibodyregistry.org/AB_2750880

Proper Citation: Cell Signaling Technology Cat# 12793, RRID:AB_2750880

Target Antigen: Glutamate dehydrogenase 1, mitochondrial

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC

Antibody Name: Glutamate Dehydrogenase 1/2 (D9F7P)

Description: This monoclonal targets Glutamate dehydrogenase 1, mitochondrial

Target Organism: monkey, rat, mouse, human

Clone ID: (D9F7P)

Antibody ID: AB_2750880

Vendor: Cell Signaling Technology

Catalog Number: 12793

Record Creation Time: 20250819T213030+0000

Record Last Update: 20250819T231120+0000

Ratings and Alerts

No rating or validation information has been found for Glutamate Dehydrogenase 1/2 (D9F7P).

No alerts have been found for Glutamate Dehydrogenase 1/2 (D9F7P).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Mao Y, et al. (2026) B cell deficiency limits exercise capacity by remodeling liver glutamate metabolism. *Cell*, 189(11), 3254.

Young TA, et al. (2024) Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma. *bioRxiv : the preprint server for biology*.

Guo M, et al. (2023) Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control. *Cell reports*, 42(9), 113047.

Lu T, et al. (2023) Gut Microbiota-Derived Glutamine Attenuates Liver Ischemia/Reperfusion Injury via Macrophage Metabolic Reprogramming. *Cellular and molecular gastroenterology and hepatology*, 15(5), 1255.

Xu W, et al. (2023) GOT1 regulates CD8+ effector and memory T cell generation. *Cell reports*, 42(1), 111987.

Olukoya AO, et al. (2023) Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. *Journal of the Endocrine Society*, 7(10), bvad117.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. *Science advances*, 8(39), eabq0117.

Boukouris AE, et al. (2022) A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer. *Cell reports*, 38(11), 110511.